

**ALTRES PUBLICACIONS**  
**OTRAS PUBLICACIONES**  
**OTHER PUBLICATIONS**

- Laura Fernández-Fernández, Montse Solé, Irene Bolea, Tony Valente, José C.E.Serrano, Mariona Jové, Bartolomé Ramirez, Neus Anglés, Jordi Reguant, José Ramón Morelló, Reinald Pamplona, Manuel Portero-Otin and Mercedes Unzeta.

*The Antioxidant Effect of LMN Diet, Rich in Polyphenols and Polyunsaturated Fatty Acids, in Alzheimer's Disease.*

Diet and Nutrition in Dementia and Cognitive Decline. ISBN: 978-0-12-407824-6. Chapter 78, pages 847-857. **2014**

- Solé M, Miñano-Molina AJ, Unzeta M.

*A cross-talk between A $\beta$  and endothelial SSAO/VAP-1 accelerates vascular damage and A $\beta$  aggregation related to CAA-AD.*

Neurobiol Aging. **2014** [Epub ahead of print]

- Bautista-Aguilera OM, Esteban G, Chioua M, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Soriano E, Samadi A, Unzeta M, Marco-Contelles J.

*Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.*

Drug Des Devel Ther. 8:1893-910, **2014** eCollection 2014.

- Wang L, Esteban G, Ojima M, Bautista-Aguilera OM, Inokuchi T, Moraleda I, Iriepa I, Samadi A, Youdim MB, Romero A, Soriano E, Herrero R, Fernández Fernández AP, Ricardo-Martínez-Murillo, Marco-Contelles J, Unzeta M.

*Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.*

Eur J Med Chem. **2014**;80:543-61.

- Bolea I, Colivicchi MA, Ballini C, Marco-Contelles J, Tipton KF, Unzeta M, Della Corte L.

*Neuroprotective effects of the MAO-B inhibitor, PF9601N, in an in vivo model of excitotoxicity*  
CNS Neurosci Ther. **2014**;20(7):641-50.

- Fogel WA, Stasiak A, Maksymowicz M, Kobos J, Unzeta M, Mussur M.

*Hepatocyte transplants improve liver function and encephalopathy in portacaval shunted rats.*

CNS Neurosci Ther. **2014**;20(7):685-91.

- Esteban G, Allan J, Samadi A, Mattevi A, Unzeta M, Marco-Contelles J, Binda C, Ramsay RR.  
*Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease.*  
Biochim Biophys Acta. **2014**;1844(6):1104-10.
- Bautista-Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Samadi A, Soriano E, Unzeta M, Marco-Contelles J.  
*Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.*  
Eur J Med Chem. **2014**;75:82-95.
- Sun P, Solé M, Unzeta M.  
*Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.*  
Cerebrovasc Dis. **2014**;37(3):171-80.
- Stasiak A, Mussur M, Unzeta M, Samadi A, Marco-Contelles JL, Fogel WA.  
*Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia.*  
Curr Pharm Des. **2014**;20(2):161-71.
- Bolea I, Gella A, Monjas L, Pérez C, Rodríguez-Franco MI, Marco-Contelles J, Samadi A, Unzeta M.  
*Multipotent, permeable drug ASS234 inhibits A $\beta$  aggregation, possesses antioxidant properties and protects from A $\beta$ -induced apoptosis in vitro.*  
Curr Alzheimer Res. **2013**;10(8):797-808.
- Hadjipavlou-Litina D, Samadi A, Unzeta M, Marco-Contelles J.  
*Analysis of the antioxidant properties of differently substituted 2- and 3-indolyl carbohydrazides and related derivatives.*  
Eur J Med Chem. **2013**;63:670-4.
- Gella A, Solé M, Bolea I, Ventriglia M, Siotto M, Durany N, Squitti R, Unzeta M.  
*A comparison between radiometric and fluorimetric methods for measuring SSAO activity.*  
J Neural Transm. **2013**;120(6):1015-8.
- Giralt M, Ramos R, Quintana A, Ferrer B, Erta M, Castro-Freire M, Comes G, Sanz E, Unzeta M, Pifarré P, García A, Campbell IL, Hidalgo J.  
*Induction of atypical EAE mediated by transgenic production of IL-6 in astrocytes in the absence of systemic IL-6.*  
Glia. **2013**;61(4):587-600.

- Esteban G, Bolea I, Sun P, Solé M, Samadi A, Marco-Contelles J, Unzeta M.  
*A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.*  
J Neural Transm. **2013**;120(6):911-8.
  
- Bolea I, Gella A, Unzeta M  
*Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.*  
J Neural Transm. **2012**
  
- Valente T, Gella A, Solé M, Durany N, Unzeta M.  
*Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitus.*  
J Neurosci Res. **2012**;90(10):1989-96.
  
- Samadi A, de Los Ríos C, Bolea I, Chioua M, Iriepa I, Moraleda I, Bartolini M, Andrisano V, Gálvez E, Valderas C, Unzeta M, Marco-Contelles J.  
*Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.*  
Eur J Med Chem. **2012**;52:251-62.
  
- Hernandez-Guillamon M, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, Penalba A, García S, Flores A, Ribó M, Alvarez-Sabin J, Ortega-Aznar A, Unzeta M, Montaner J.  
*VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke.*  
Cerebrovasc Dis. **2012**;33(1):55-63.
  
- Fernández-Fernández L, Comes G, Bolea I, Valente T, Ruiz J, Murtra P, Ramirez B, Anglés N, Reguant J, Morelló JR, Boada M, Hidalgo J, Escorihuela RM, Unzeta M.  
*LMN diet, rich in polyphenols and polyunsaturated fatty acids, improves mouse cognitive decline associated with aging and Alzheimer's disease.*  
Behav Brain Res. **2012**.17;228(2):261-71.
  
- Stasiak A, Mussur M, Unzeta M, Lazewska D, Kiec-Kononowicz K, Fogel WA.  
*The central histamine level in rat model of vascular dementia.*  
J Physiol Pharmacol. **2011**;62(5):549-58.

- Samadi A, Chioua M, Bolea I, de los Ríos C, Iriepa I, Moraleda I, Bastida A, Esteban G, Unzeta M, Gálvez E, Contelles J.M.

*Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.*

Eur J Med Chem. **2011**;46(9):4665-8.

- Unzeta M, Sanz E.

*Novel MAO-B inhibitors potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.*

Int Rev Neurobiol. **2011**;100:217-36.

- Solé M, Unzeta M.

*Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases.*

Biol Cell. **2011**;103(11):543-57.

- Bolea I, Juárez-Jiménez J, de Los Ríos C, Chioua M, Pouplana R, Luque FJ, Unzeta M, Marco-Contelles J, Samadi A.

*Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer's Disease.*

J Med Chem. **2011** 22;54(24):8251-8270.

- Valente T, Solé M, Gella A, Durany N, Unzeta M.

*SSAO and A BETA in the vascular damage of the temporal cortex from alzheimer and alzheimer with diabetes patients*

Alzheimer's disease research journal, **2011**, 3.

- M, Ortega-Aznar A, Domínguez C, Rubiera M, Ribó M, Quintana M, Molina CA, Alvarez-Sabín J, Rosell A, Unzeta M, Montaner J.

*Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.*

Stroke. **2010**; 41(7):1528-35.

- Bellik L, Dragoni S, Pessina F, Sanz E, Unzeta M, Valoti M.

*Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species.*

Acta Biochim Pol. **2010**; 57(2):235-9.

- Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N.  
*Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus.*  
Neurobiol Dis. **2010**; 37(1):67-76.
  
- Sanz E, Quintana A, Valente T, Manso Y, Hidalgo J, Unzeta M.  
*Monoamine oxidase-B activity is not involved in the neuroinflammatory response elicited by a focal freeze brain injury.*  
J Neurosci Res. **2009**;15;87(3):784-94.
  
- Sanz E, Quintana A, Hidalgo J, Marco JL, Unzeta M.  
*PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent neuroprotection in ER stress-induced cell death.*  
Mol Cell Neurosci. **2009**;41(1):19-31.
  
- Valente T, Hidalgo J, Bolea I, Ramírez B, Anglés N, Reguant J, Morelló JR, Gutiérrez C, Boada M, Unzeta M.  
*A Diet Enriched in Polyphenols and Polyunsaturated Fatty Acids, LMN Diet, Induces Neurogenesis in the Subventricular Zone and Hippocampus of Adult Mouse Brain.*  
Alzheimers Dis. **2009**;18:849-865
  
- Sanz E, Hofer MJ, Unzeta M, Campbell IL.  
*Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain.*  
Glia. **2008**;56(2):190-9.
  
- Sanz E, Quintana A, Battaglia V, Toninello A, Hidalgo J, Ambrosio S, Valoti M, Marco JL, Tipton KF, Unzeta M.  
*Anti-apoptotic effect of MAO B inhibitor PF 9601N[N-(2-propynyl)-2-(5-benzyloxy-indolyl)methylamine] is mediated by p53 pathway inhibition by MPP+ treated SHSY5Y human dopaminergic cells.*  
J Neurochem. **2008**; 105: 2404-2417.
  
- Solé M, Hernandez-Guillamon M, Boada M, Unzeta M.  
*p53 phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1.*  
Biochim Biophys Acta 1783, 1985-1994 **2008**

- Valente T, Solé M, Unzeta M.  
*SSAO/VAP-1 protein expression during mouse embryonic development.*  
Dev Dyn. **2008**;237(9):2585-93.
- Dragoni S, Materozzi G, Pessina F, Frosini M, Marco JL, Unzeta M, Sgaragli G and Valoti M.  
*CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes.*  
J Pharm Pharm Sci. **2007**; 10(4): 473-85.
- Sanz E, Hofer MJ, Unzeta M and Campbell IL.  
*Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain.*  
Glia. **2008**; 56(2): 190-9.
- Hernandez-Guillamon M, Bolea I, Solé M, Boada M, Tipton KF and Unzeta M.  
*Sodium bicarbonate enhances membrane-bound and soluble human semicarbazide-sensitive amine oxidase activity in vitro.*  
J Biochem. **2007**; 142(5): 571-6.
- Prévot D, Soltesz Z, Abello V, Wanecq E, Valet P, Unzeta M and Carpené C.  
*Prolonged treatment with aminoguanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats.*  
Pharmacol Res. **2007**; 56(1): 70-9.
- Jones TZ, Balsa D, Unzeta M and Ramsay RR.  
*Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better.*  
J Neural Transm. **2007**; 114(6): 707-12.
- Solé M, Hernandez M, Boada M and Unzeta M.  
*Characterization of A7r5 cell line transfected in a stable form by hSSAO/VAP-1 gene (A7r5 hSSAO/VAP-1 cell line).*  
J Neural Transm. **2007**; 114(6): 763-7.
- Unzeta M, Solé M, Boada M and Hernández M.  
*Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease.*  
J Neural Transm. **2007**; 114(6): 857-62.

- Battaglia V, Sanz E, Salvi M, Unzeta M and Toninello A.  
*Protective effect of N-(2-propynyl)-2-(5-benzyloxy-indolyl)methylamine (PF9601N) on mitochondrial permeability transition.*  
Cell Mol Life Sci. **2006**; 63(12): 1440-8.
- Giménez-Xavier P, Gomez-Santos C, Castaño E, Francisco R, Boada J, Unzeta M, Sanz E and Ambrosio S.  
*The decrease of NAD(P)H has a prominent role in dopamine toxicity.*  
Biochim Biophys Acta. **2006**; 1762(5): 564-74.
- Hernandez M, Solé M, Boada M and Unzeta M.  
*Soluble semicarbazide sensitive amine oxidase (SSAO) catalysis induces apoptosis in vascular smooth muscle cells.*  
Biochim Biophys Acta. **2006**; 1763(2): 164-73.
- del Mar Hernandez M, Esteban M, Szabo P, Boada M and Unzeta M.  
*Human plasma semicarbazide sensitive amine oxidases (SSAO), beta-amyloid protein and aging.*  
Neurosci Lett. **2005**; 384(1-2): 183-7.